🟢 Abcellera Biologics is trading 7.5% up today after announcing Phase 2 ABCL635 data presentation

Abcellera Biologics is trading at $12.55 (+7.54%) after announcing it will present Phase 2 ABCL635 data at the IMS World Congress on Menopause.

• The September 17, 2026, announcement highlights efficacy and safety data for the menopause-treatment candidate, reinforcing investor interest ahead of the September 30–October 3 conference.
• A broader biotech rally and improved risk appetite after the Federal Reserve decision are also supporting the move.